EP Patent

EP2395983B1 — Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof

Assigned to Boehringer Ingelheim International GmbH · Expires 2020-04-08 · 6y expired

What this patent protects

Patent listed against Jardiance.

Drugs covered by this patent

Patent Metadata

Patent number
EP2395983B1
Jurisdiction
EP
Classification
—
Expires
2020-04-08
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.